Abstract
D-galactose is a simple and natural compound that has mainly been exploited in prodrug strategies. Galactosyl prodrugs can be considered a good approach to reach different goals in clinical drug application, especially when traditional drugs are likely to fail therapeutically owing to reasons such as the lack of site specificity, toxicity, and chemical instability. Indeed, of paramount importance is their ability to increase the selectivity of the parent compound, a phenomenon that helps to reduce the incidence of adverse effects, while preserving intact the pharmacodynamic features of the parent drug. Study results have varied according to the type of linkage between the drug and the hydroxyl group exploited. By working with these parameters, researchers have been able not only to generate selective pharmacological targeting of brain, liver, and cancerous cells, but also to improve cellular permeability as well as the pharmacokinetic profile of parent drugs. This review describes the broad spectrum of possibilities for exploiting D-galactose as a vector for prodrug design and the synthetic strategies that allow its realization.
Keywords: Galactosyl prodrugs, drug targeting, cell permeability, pharmacokinetic improvement, toxicity, and chemical instability, pharmacodynamic, cancerous cells, synthetic strategies, potential moieties, prodrug synthesis, mesencephalon, electrochemical detector, antioxidant enzyme, carboxylic group, synthesizing galactos
Current Topics in Medicinal Chemistry
Title: D-Galactose as a Vector for Prodrug Design
Volume: 11 Issue: 18
Author(s): Daniela Melisi, Annalisa Curcio, Elvira Luongo, Elena Morelli and Maria Grazia Rimoli
Affiliation:
Keywords: Galactosyl prodrugs, drug targeting, cell permeability, pharmacokinetic improvement, toxicity, and chemical instability, pharmacodynamic, cancerous cells, synthetic strategies, potential moieties, prodrug synthesis, mesencephalon, electrochemical detector, antioxidant enzyme, carboxylic group, synthesizing galactos
Abstract: D-galactose is a simple and natural compound that has mainly been exploited in prodrug strategies. Galactosyl prodrugs can be considered a good approach to reach different goals in clinical drug application, especially when traditional drugs are likely to fail therapeutically owing to reasons such as the lack of site specificity, toxicity, and chemical instability. Indeed, of paramount importance is their ability to increase the selectivity of the parent compound, a phenomenon that helps to reduce the incidence of adverse effects, while preserving intact the pharmacodynamic features of the parent drug. Study results have varied according to the type of linkage between the drug and the hydroxyl group exploited. By working with these parameters, researchers have been able not only to generate selective pharmacological targeting of brain, liver, and cancerous cells, but also to improve cellular permeability as well as the pharmacokinetic profile of parent drugs. This review describes the broad spectrum of possibilities for exploiting D-galactose as a vector for prodrug design and the synthetic strategies that allow its realization.
Export Options
About this article
Cite this article as:
Melisi Daniela, Curcio Annalisa, Luongo Elvira, Morelli Elena and Grazia Rimoli Maria, D-Galactose as a Vector for Prodrug Design, Current Topics in Medicinal Chemistry 2011; 11 (18) . https://dx.doi.org/10.2174/156802611797183258
DOI https://dx.doi.org/10.2174/156802611797183258 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Oxidative Stress, Endothelial Dysfunction and Atherosclerosis
Current Pharmaceutical Design The Chemosensitizing Role of Metformin in Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances of Novel Therapeutic Agents from Botanicals for Prevention and Therapy of Breast Cancer: An Updated Review
Current Cancer Therapy Reviews Synthesis, Structure and Antibacterial Evaluation of Some N-substituted 3-amino-5-hydroxy-4-phenyl-1H-pyrazole-1-carboxamides
Medicinal Chemistry Dose and Sequence Dependent Synergism from the Combination of Oxaliplatin with Emetine and Patulin Against Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics